Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

84.53
Delayed Data
As of May 27
 +2.75 / +3.36%
Today’s Change
55.00
Today|||52-Week Range
133.62
-22.06%
Year-to-Date
Investors Eager for Gilead to Make Big Moves
May 26 / TheStreet.com - Paid Partner Content
Gilead (GILD) Shares Spike After Exec. Board Appointment
May 25 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close81.78
Today’s open81.69
Day’s range80.95 - 85.68
Volume1,210,382
Average volume (3 months)1,964,775
Market cap$15.9B
Dividend yield--
Data as of 3:59pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+145.45%
Earnings growth (next 5 years)+56.00%
Revenue growth (last year)+47.36%
P/E ratio332.4
Price/Sales26.95
Price/Book92.18

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+1.83+2.10%
PRGOPerrigo Company PLC+0.41+0.43%
MDVNMedivation Inc+0.32+0.53%
MYLMylan NV+0.20+0.47%
Data as of 4:02pm ET, 05/27/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.02
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts

Partner Offers

Search for Jobs